This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Revance Therapeutics Class Action Lawsuit
Business class action

Revance Therapeutics Class Action Lawsuit

Analysis based on 6 articles · First reported Feb 03, 2025 · Last updated Feb 26, 2025

Sentiment
-40
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Revance Therapeutics, Inc. is expected to negatively impact its stock price and reputation due to allegations of false statements and breach of contract. This event highlights the risks associated with undisclosed material breaches for publicly traded companies.

Pharmaceuticals Legal Services
Event Summary

The Gross Law Firm has issued multiple notices to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC) regarding a pending class action lawsuit. The lawsuit alleges that Revance Therapeutics, Inc. made materially false and misleading statements and failed to disclose a material breach of its Distribution Agreement with Teoxane. This breach, concerning the exclusive distribution rights for Teoxane's dermal fillers, subjected Revance Therapeutics, Inc. to increased litigation risk, monetary, and reputational harm, potentially delaying or amending a tender offer. The class period for affected shareholders is from February 29, 2024, to December 6, 2024, with a lead plaintiff deadline of March 4, 2025.

Key Actions
90 Revance Therapeutics concealed material breach Teoxane
Entities Involved
stock
Revance Therapeutics
Revance Therapeutics, Inc. is facing a class action lawsuit for allegedly issuing materially false and/or misleading statements and failing to disclose a material breach of its Distribution Agreement with Teoxane, which could lead to significant financial and reputational harm.
Importance 100.0 Sentiment -60.0
priv
Teoxane
Revance Therapeutics, Inc. was allegedly in material breach of its Distribution Agreement with Teoxane, which granted Revance Therapeutics, Inc. exclusive distribution rights for Teoxane's dermal fillers.
Importance 40.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.